Impavido (Miltefosine) Patent Expiration, LOE Window & CMS Spending

Impavido (Miltefosine) by Knight Therapeutics Usa: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $1.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKnight Therapeutics Usa
FDA Application & PathwayN204684 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.5M
2024 Medicare Part D Spend$1.5M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel